OwlTail

Cover image of Arjun Balar

Arjun Balar

20 Podcast Episodes

Latest 22 Jan 2022 | Updated Daily

Weekly hand curated podcast episodes for learning

Episode artwork

Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting with Dr Arjun Balar

Prostate Cancer Update

Featuring a discussion on important datasets on genitourinary cancers from the 2021 ASCO Annual Meeting with Dr Arjun Balar, moderated by Neil Love, MD.

51mins

15 Jul 2021

Episode artwork

Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting with Dr Arjun Balar

Oncology Today with Dr Neil Love

Dr Arjun Balar from the NYU Perlmutter Cancer Center in New York discusses key presentations on genitourinary cancers from the 2021 ASCO Annual Meeting. CME information and select publications here.

51mins

15 Jul 2021

Similar People

Episode artwork

Advanced bladder cancer: Dr. Arjun Balar talks treatment strategies in a changing field

Blood & Cancer

Systemic treatment for advanced urothelial cancer is quickly evolving. On this week’s podcast, Arjun Balar, MD, director of the genitourinary medical oncology program at New York University discusses his approach amid changing times with guest host Alan Lyss, MD, a community-based medical oncologist and clinical researcher in the St. Louis area before his recent retirement.  Chemotherapy or immunotherapy first line? With the negative phase 3 results for chemotherapy in combination with either pembrolizumab or atezolizumab, “if I use immunotherapy, I use it alone,” Dr. Balar said. Patients who need “a response right away” for aggressive disease get chemotherapy. In general, first-line chemotherapy “probably is the better route for a lot of people,” he said. There is a role for immunotherapy in the first line when chemotherapy can’t be tolerated because of age or other reasons, and in the second line, immunotherapy is standard of care. PD-1/PD-LI expression is too inconsistent to help guide the decision. It’s based instead on clinical judgement, given patient and disease characteristics. Antibody-drug conjugates The class includes enfortumab vedotin and sacituzumab govitecan, both approved for third-line treatment after chemo and immunotherapy. Essentially, they are homing molecules targeting cancer-specific antigens coupled with a potent cytotoxic payload. They have strong potential in combination with immunotherapy. “I think, in the next 3-5 years, we're going to find ADCs plus immunotherapy become the new standard of care,” Dr. Balar said. New enfortumab vedotin data show activity in the second line among medically frail patients ineligible for chemotherapy who were treated instead with immunotherapy for metastatic disease. “This drug can potentially rescue those patients as an option after immunotherapy,” said Dr. Balar, an enfortumab vedotin investigator. Next-generation sequencing There’s no role yet for sequencing in the first line, but it’s necessary in later lines to check eligibility for drugs aimed at specific mutations, such as the tyrosine kinase inhibitor erdafitinib for patients with susceptible FGFR3 or FGFR2 genetic alterations. Assays are available commercially from Foundation and other companies. Results can take up to 6 weeks, so “I do it early on. I know that information is potentially going to be useful in making treatment decisions,” Dr. Balar said. Enfortumabe vedotin adverse events Side effects can include hyperglycemia within the first one or two cycles. Sometimes it’s asymptomatic, sometimes it’s accompanied by acid-base disturbances, and in very rare cases, it’s fatal. The problem is possibly linked to higher baseline body mass index. At least half of patients develop a sunburn-like rash, also within the first one or two cycles, that spares the face and can be pruritic. It’s manageable by topical steroids, oral antihistamines, dose reductions, or dose interruptions. “If anything severe is going to happen, it's going to happen within the first one or two cycles. I see [patients at] every visit” in the first two cycles “primarily to catch anything untoward,” Dr. Balar said. Neuropathy is the “most significant dose-limiting toxicity, and tends to develop about 4 months into treatment,” he said. Show notes written by M. Alexander Otto. Dr. Balar disclosed research, advisory, and/or speaker relationships with Genentech, Incyte, Bristol-Myers Squibb, Janssen, Merck, Pfizer, AstraZeneca, and other companies. Dr. Lyss writes a column for MDedge Hematology/Oncology called “Clinical Insights” and had no other conflicts of interest.

27mins

20 May 2021

Episode artwork

Urothelial Bladder Carcinoma | Arjun Balar, MD

Research To Practice | Oncology Videos

Recent Advances in Medical Oncology: Urothelial Bladder Carcinoma — Faculty Presentation 1: Current Role and Ongoing Investigation of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer — Dr Balar. CME information and select publications

42mins

2 Dec 2020

Most Popular

Episode artwork

Arjun Balar, MD - Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy

PeerView Clinical Pharmacology CME/CNE/CPE Video

Go online to PeerView.com/MMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody–drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.

1hr 9mins

4 Sep 2020

Episode artwork

Arjun Balar, MD - Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/MMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody–drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.

1hr 9mins

4 Sep 2020

Episode artwork

Arjun Balar, MD - Evidence and Insights on Innovative Treatment for Bladder Cancer: Clinical Breakthroughs From Targeted and Immune Options to Antibodies and Gene Therapy

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/MMX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in bladder cancer present real-world applications of emerging data for innovative therapeutics to offer practical strategies for developing sound, evidence-based protocols to provide more potent and effective treatment options to patients with bladder cancer. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody–drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.

1hr 9mins

4 Sep 2020

Episode artwork

Bladder Cancer | Arjun Balar, MD

Research To Practice | Oncology Videos

The Current and Future Role of Immune Checkpoint Inhibitors and Other Novel Therapies in Urothelial Bladder Cancer — Faculty Presentation #1: Optimal Application of Immune Checkpoint Inhibitors in Advanced Urothelial Cancer — Dr Balar CME information and select publications

46mins

13 Aug 2020

Episode artwork

Arjun Balar, MD - Innovative Treatments for Bladder Cancer: Thoughts From the Chair

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/YFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led bladder cancer program, Dr. Arjun Balar discusses recent updates from the 2020 American Society of Clinical Oncology Annual Meeting and reviews new evidence on the continuing integration of novel therapeutics, including immunotherapy, targeted agents, and antibody-based approaches, across a wide range of bladder cancer treatment settings. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.

25mins

27 Jul 2020

Episode artwork

Arjun Balar, MD - Innovative Treatments for Bladder Cancer: Thoughts From the Chair

PeerView Internal Medicine CME/CNE/CPE Video Podcast

Go online to PeerView.com/YFM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this expert-led bladder cancer program, Dr. Arjun Balar discusses recent updates from the 2020 American Society of Clinical Oncology Annual Meeting and reviews new evidence on the continuing integration of novel therapeutics, including immunotherapy, targeted agents, and antibody-based approaches, across a wide range of bladder cancer treatment settings. Upon completion of this activity, participants should be better able to: Discuss the current therapeutic role of novel agents in advanced bladder cancer over multiple lines of treatment and across patient populations, Summarize updated evidence about the use of novel therapies, including immune checkpoint inhibitors, targeted agents, antibody-drug conjugates, and gene therapy across the spectrum of bladder cancer settings, Recommend patient-appropriate novel therapeutics for the management of bladder cancer, Manage unique adverse events associated with novel immune-, targeted-, antibody-, and gene therapy-based treatments for bladder cancer.

25mins

27 Jul 2020

Loading